PEPG — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• In May 2022, we closed our initial public offering, or IPO, in which we sold an aggregate of 9,000,000 shares of common stock at a public offering price of $12.00 per share for gross proceeds of $108.0 million. In connection with the IPO, we granted the

• underwriters a 30-day option to purchase 1,350,000 additional shares of common stock, which they exercised in part to purchase 1,238,951 additional shares of common stock for gross proceeds of $14.9 million. We received approximately $122.9 million in gross proceeds and $110.2 million in net proceed…

• Interest income consists of interest earned on our cash equivalents and marketable securities.

• Research and development expenses decreased by $5.9 million from $18.4 million for the three months ended June 30, 2025, to $12.5 million for the three months ended June 30, 2026. This was primarily attributable to a $2.3 million decrease in clinical trial expense as, prior to the discontinuation of…

• General and administrative expenses increased by $0.9 million from $5.5 million for the three months ended June 30, 2025, to $6.4 million for the three months ended June 30, 2026. The increase was primarily driven by an increase of $0.7 million in personnel-related costs, including $0.6 million in s…

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• In May 2022, we closed our initial public offering, or IPO, in which we sold an aggregate of 9,000,000 shares of common stock at a public offering price of $12.00 per share for gross proceeds of $108.0 million. In connection with the IPO, we granted the underwriters a 30-day option to purchase 1,350…

• Interest income consists of interest earned on our money market mutual funds and short-term U.S. treasury holdings.

• Research and development expenses decreased by $12.4 million from $25.4 million for the three months ended March 31, 2025, to $13.0 million for the three months ended March 31, 2026. This was primarily attributable to a $9.7 million decrease in manufacturing costs related to the timing of manufactur…

• General and administrative expenses remained flat from $5.9 million for the three months ended March 31, 2025, to $5.9 million for the three months ended March 31, 2026.

• Other income (expense), net was $1.2 million for the three months ended March 31, 2026 and $1.1 million for the three months ended March 31, 2025. Interest is earned through our cash deposits and U.S. Treasury-backed money market funds.

Text added vs the prior filing · source: 10-Q · 2026-08-06

• successful clinical development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.

• Commencing clinical trials in the U.S. is subject to authorization by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies, or we are required to satisfy …

• Commercialization of our product candidates will require preclinical and clinical development; regulatory approval; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of our current and future product candidates will depend on many…

• Further, conducting clinical trials in foreign countries, as we plan to continue to do for our product candidates, including PGN-EDODM1, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to …

• Additionally, our planned clinical trials may utilize an “open-label” trial design. An “open-label” clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically…

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• Commencing clinical trials in the U.S. is subject to authorization by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies, or we are required to satisfy …

• Commercialization of our product candidates will require preclinical and clinical development; regulatory approval; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of our product candidates will depend on many factors, including…

• Further, conducting clinical trials in foreign countries, as we plan to continue to do for our product candidates, including PGN-EDODM1, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients

• in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.

• Additionally, our planned clinical trials may utilize an “open-label” trial design. An “open-label” clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically…